Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

New additions to the Adis Journal Club – November update

Browse November's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER. Read more

Initiating GLP-1 receptor agonists: Managing side effects

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

Hot topic review

How far has immunotherapy for type 1 diabetes progressed?

Read our Hot Topic Review for a rapid update on the successes and failures of immunotherapies in people with or at high risk for type 1 diabetes.

View from the clinic

Managing hyperglycemia in the face of a high-carbohydrate diet

Sanjay Kalra considers the course of action when blood glucose remains high in someone who cannot, or will not, modify a high-carbohydrate diet. Read more

Content hub

The challenge of type 2 diabetes in children

Who is at the highest risk for developing type 2 diabetes in their youth? What are the consequences of being diagnosed so young, and what can clinicians do to help? Browse the hub to find out

WEBINAR SERIES | Cushing’s Hub

The Cushing’s Hub Editorial Board is delighted to host its first webinar on Friday 16 December 2022 at 13.00-14.00 hours Central European Time.

Chaired by Dr Niki Karavitaki, University of Birmingham, UK, hear panellists Prof Dr Stephan Petersenn, Hamburg, Germany, Prof Antoine Tabarin, Bordeaux, France and Assoc Prof Dr Greisa Vila, Vienna, Austria, explain the challenges surrounding the clinical management of Cushing’s syndrome and take questions from the audience.

EACCME® accreditation applied for.

Click here for more information

IN FOCUS | GLP-1 receptor agonists

Syringe and pills

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

IN FOCUS | Obesity & lifestyle interventions

Syringe and pills

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

IN FOCUS | Pediatric type 2 diabetes

Weekly pill container

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

IN FOCUS | Hyperglycemia

X-ray of fractured forearm shaft of radius and ulnar bone on red mark

05-24-2022 | Bone health | News

Poor glycemic control, kidney disease linked to bone fragility in type 1 diabetes

Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.

IN FOCUS | Cardiovascular disorders

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

IN FOCUS | Hypoglycemia

White plate with spoon and fork in clock formation, fasting concept

03-31-2022 | Diet | Hot topic review | Article

Fasting and people with diabetes

Read this Hot Topic Review to catch up on the latest research into the risks and benefits of fasting for people with diabetes.

IN FOCUS | Tirzepatide

Person standing on weigh scales with tape measure in foreground

06-04-2022 | ADA 2022 | Conference coverage | News

​​​​​​​SURMOUNT-1 places tirzepatide weight loss efficacy within surgical range

A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.

IN FOCUS | Kidney disease

Close up of urinalysis with reagent strips

11-10-2022 | Nephropathy | News

‘Strong justification’ for individualized albuminuria screening in type 1 diabetes

Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.

IN FOCUS | SGLT2 inhibitors

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

IN FOCUS | Mental health & psychosocial care

Lori Berard

04-14-2022 | Hyperglycemia | View from the clinic | Article

Managing hyperglycemia related to stress

Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.

IN FOCUS | Diabetes devices & technology

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.